Sort   by:  
 Page size 
UnknownUnveiling preferences in multiple sclerosis care: insights from an Italian discrete-choice experiment with patients and healthcare professionals.
Not available
S-EPMC11638307 | biostudies-literature
UnknownBody mass index is not associated with survival outcomes and immune-related adverse events in patients with Hodgkin lymphoma treated with the immune checkpoint inhibitor nivolumab.
Not available
S-EPMC8638339 | biostudies-literature
UnknownEarly and unrestricted access to high-efficacy disease-modifying therapies: a consensus to optimize benefits for people living with multiple sclerosis.
Not available
S-EPMC8501364 | biostudies-literature
UnknownPrevalence, Clustering, and Current Management of Cardiovascular Risk Factors Upon First Referral to Hypertension Specialists: the APPROACH Study.
Not available
S-EPMC11322322 | biostudies-literature
UnknownMore Than the Sum of Its Parts: Disrupted Core Periphery of Multiplex Brain Networks in Multiple Sclerosis.
Not available
S-EPMC11685378 | biostudies-literature
UnknownAnti-PD1 Consolidation in Patients with Hodgkin Lymphoma at High Risk of Relapse after Autologous Stem Cell Transplantation: A Multicenter Real-Life Study.
Not available
S-EPMC9739754 | biostudies-literature
UnknownSafety and Efficacy of Tinostamustine in a Subpopulation of Patients With Relapsed/Refractory Hodgkin Lymphoma From a Phase I Trial.
Not available
S-EPMC11609130 | biostudies-literature
UnknownImpact of cemiplimab treatment duration on clinical outcomes in advanced cutaneous squamous cell carcinoma.
Not available
S-EPMC11162402 | biostudies-literature
UnknownCOVID-19 pandemic and mental distress in multiple sclerosis: Implications for clinical management.
Not available
S-EPMC7675416 | biostudies-literature
UnknownA Combined Proteomic and Transcriptomic Signature Is Predictive of Response to Anti-PD-1 Treatment: A Retrospective Study in Metastatic Melanoma Patients.
Not available
S-EPMC11395026 | biostudies-literature
Sort   by:  
 Page size